Form 4 for GILD Gilead Sciences
Accepted 2024-12-03 00:00:00 ET · period of report 2024-11-29 · accession 0001127602-24-028397 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-12-03 | 2024-11-29 | GILD | Dickinson Andrew D | CFO | M - OptEx | $70.50 | +248.6K | 157.5K | New | +$17.53M |
| DM | 2024-12-03 | 2024-11-29 | GILD | Dickinson Andrew D | CFO | S - Sale+OE | $92.76 | -248.6K | 266.8K | -48% | -$23.07M |
| DM | 2024-12-03 | 2024-11-29 | GILD | Dickinson Andrew D | CFO | M - OptEx | $0.00 | -248.6K | 130.9K | -66% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-11-29 | M | A | 26,170 | $57.92 | 183,719 | D | — | — | |
| 2 | Common | Common Stock | 2024-11-29 | M | A | 33,660 | $68.75 | 217,379 | D | — | — | |
| 3 | Common | Common Stock | 2024-11-29 | M | A | 65,960 | $72.70 | 387,564 | D | — | — | |
| 4 | Common | Common Stock | 2024-11-29 | M | A | 43,340 | $72.70 | 321,604 | D | — | — | |
| 5 | Common | Common Stock | 2024-11-29 | M | A | 60,885 | $71.91 | 278,264 | D | — | — | |
| 6 | Common | Common Stock | 2024-11-29 | S | D | 127,930 | $92.76 | 138,919 | D | — | — | (F3) Sales prices reported for the transactions reported here range from $92.33 to $93.09. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. |
| 7 | Common | Common Stock | 2024-11-29 | S | D | 120,715 | $92.77 | 266,849 | D | — | — | (F2) Sales prices reported for the transactions reported here range from $92.36 to $93.09. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. |
| 8 | Common | Common Stock | 2024-11-29 | M | A | 18,630 | $73.77 | 157,549 | D | — | — | |
| 9 | Derivative | Non-qualified Stock Option (Right to Buy) | 2024-11-29 | M | D | 65,960 | $0.00 | 0 | D | $72.70 · — to 2026-12-10 | 65,960 Common Stock | (F4) The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
| 10 | Derivative | Non-qualified Stock Option (Right to Buy) | 2024-11-29 | M | D | 43,340 | $0.00 | 0 | D | $72.70 · — to 2027-08-10 | 43,340 Common Stock | (F5) The shares subject to the option have a three year vesting schedule. 33.33% vest on the first anniversary of the date of the grant. The balance will vest 8.33% quarterly thereafter until fully vested. |
| 11 | Derivative | Non-qualified Stock Option (Right to Buy) | 2024-11-29 | M | D | 60,885 | $0.00 | 0 | D | $71.91 · — to 2028-06-10 | 60,885 Common Stock | (F4) The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
| 12 | Derivative | Non-qualified Stock Option (Right to Buy) | 2024-11-29 | M | D | 33,660 | $0.00 | 0 | D | $68.75 · — to 2029-02-06 | 33,660 Common Stock | (F4) The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
| 13 | Derivative | Non-qualified Stock Option (Right to Buy) | 2024-11-29 | M | D | 18,630 | $0.00 | 0 | D | $73.77 · — to 2027-11-10 | 18,630 Common Stock | (F5) The shares subject to the option have a three year vesting schedule. 33.33% vest on the first anniversary of the date of the grant. The balance will vest 8.33% quarterly thereafter until fully vested. |
| 14 | Derivative | Non-qualified Stock Option (Right to Buy) | 2024-11-29 | M | D | 26,170 | $0.00 | 130,860 | D | $57.92 · — to 2032-03-10 | 26,170 Common Stock | (F4) The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |